TNSN97086A1 - THE SUBSTITUTION OF 4-ALBUTYRIC DERIVATIVE ACIDS AS INHIBITORS OF THE METALLOPROTEASE MATRIX. - Google Patents

THE SUBSTITUTION OF 4-ALBUTYRIC DERIVATIVE ACIDS AS INHIBITORS OF THE METALLOPROTEASE MATRIX.

Info

Publication number
TNSN97086A1
TNSN97086A1 TNTNSN97086A TNSN97086A TNSN97086A1 TN SN97086 A1 TNSN97086 A1 TN SN97086A1 TN TNSN97086 A TNTNSN97086 A TN TNSN97086A TN SN97086 A TNSN97086 A TN SN97086A TN SN97086 A1 TNSN97086 A1 TN SN97086A1
Authority
TN
Tunisia
Prior art keywords
alkyl
phenyl
inhibitors
pharmaceutically acceptable
albutyric
Prior art date
Application number
TNTNSN97086A
Other languages
French (fr)
Inventor
C E Kiuender Harold
r dixon Brian
r brittelli David
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of TNSN97086A1 publication Critical patent/TNSN97086A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines

Abstract

LES INHIBITEURS DES MATRICES METALLOPROTEASES. DES COMPOSITIONS PHARMACEUTIQUES LES PORTANT. ET UN PROCESSUS POUR LES UTILISER AFIN DE TRAITER UNE VARIETE DES CONDITIONS PHYSIOLOGIQUE. LES COMPOSES DE CETTE INVENTION ONT LA FORMULE GENERALISEE (1) : OU R1 REPRESENTE C6-C12 ALKYL ; C5-C12 ALKOXY ; C5-C12 ALKYLTHIO ; UNE FORMULE DE POLYETHER R2O(C2H4O)a- OU a EST 1 OU 2 ET R2 EST C1-C5 ALKYL ET LA FORMULE ALKENYL SUBSTITUTEE R3 (CH2)b-C = C- ; OU b EST 1-10 ET R3 EST H-, HO- OU R4O- OU R4 EST C1- C3 ALKYL, PHENYL OU BENZYL. LES PORTIONS ALKYL, PHENYL, OU BENZYL DE R4 SUPPORTE AU MOINS UN SUBUSTITUENT PHARMACEUTIQUEMENT ACCEPTABLE. LE SUBSTITUTENT n EST 2-4. R5 REPRESENTE LE PHENYL ; IMIDOYL DE 4-12 CARBONS D'ATOMES : (3H)-BENZO-1,2,3-TRIAZIN-4- ON -3-YL ; N-SACCHARINYL ; (2H)-PHTHALAZIN-1-ON-2-YL ;2-BENZOXAZOLIN-2-ON-3yL ; 5,5- DIMETHYLOXAZOLIDINE-2,4-DION-3-YL ; ET THIAZOLIDINE-2,4-DION-3-YL ; AVEC DES PORTIONS DE PHENYL ET BENZO DE R5 SUPPORTANT PERMISSIBLEMENT UN SUBSTITUENT PHARMACEUTIQUEMENT ACCEPTABLE. LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES MATIERES SONT AUSSI INCLUS.INHIBITORS OF METALLOPROTEASE MATRICES. PHARMACEUTICAL COMPOSITIONS WEARING THEM. AND A PROCESS FOR USING THEM TO TREAT A VARIETY OF PHYSIOLOGICAL CONDITIONS. THE COMPOUNDS OF THIS INVENTION HAVE THE GENERALIZED FORMULA (1): OR R1 REPRESENTS C6-C12 ALKYL; C5-C12 ALKOXY; C5-C12 ALKYLTHIO; A POLYETHER FORMULA R2O (C2H4O) a- OR a IS 1 OR 2 AND R2 IS C1-C5 ALKYL AND THE ALKENYL SUBSTITUTED FORMULA R3 (CH2) b-C = C-; OR b IS 1-10 AND R3 IS H-, HO- OR R4O- OR R4 IS C1- C3 ALKYL, PHENYL OR BENZYL. THE ALKYL, PHENYL, OR BENZYL PORTIONS OF R4 SUPPORT AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE SUBSTANT. THE SUBSTITUTE IS 2-4. R5 REPRESENTS PHENYL; IMIDOYL OF 4-12 CARBONS OF ATOMS: (3H) -BENZO-1,2,3-TRIAZIN-4- ON -3-YL; N-SACCHARINYL; (2H) -PHTHALAZIN-1-ON-2-YL; 2-BENZOXAZOLIN-2-ON-3yL; 5.5- DIMETHYLOXAZOLIDINE-2,4-DION-3-YL; AND THIAZOLIDINE-2,4-DION-3-YL; WITH R5 PHENYL AND BENZO PORTIONS PERMISSIBLY SUPPORTING A PHARMACEUTICALLY ACCEPTABLE SUBSTITUTE. PHARMACEUTICALLY ACCEPTABLE SALTS OF THESE MATERIALS ARE ALSO INCLUDED.

TNTNSN97086A 1996-05-15 1997-05-09 THE SUBSTITUTION OF 4-ALBUTYRIC DERIVATIVE ACIDS AS INHIBITORS OF THE METALLOPROTEASE MATRIX. TNSN97086A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64768296A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
TNSN97086A1 true TNSN97086A1 (en) 2005-03-15

Family

ID=24597888

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97086A TNSN97086A1 (en) 1996-05-15 1997-05-09 THE SUBSTITUTION OF 4-ALBUTYRIC DERIVATIVE ACIDS AS INHIBITORS OF THE METALLOPROTEASE MATRIX.

Country Status (21)

Country Link
EP (1) EP0923529B1 (en)
JP (1) JP3354941B2 (en)
CN (1) CN1225620A (en)
AR (1) AR007101A1 (en)
AT (1) ATE205822T1 (en)
AU (1) AU727468B2 (en)
BR (1) BR9709075A (en)
CA (1) CA2253795C (en)
CO (1) CO5011113A1 (en)
DE (1) DE69706874T2 (en)
ES (1) ES2160955T3 (en)
HR (1) HRP970247B1 (en)
ID (1) ID17326A (en)
MY (1) MY116903A (en)
PA (1) PA8429501A1 (en)
SV (1) SV1997000033A (en)
TN (1) TNSN97086A1 (en)
TW (1) TW442468B (en)
WO (1) WO1997043237A1 (en)
YU (1) YU18897A (en)
ZA (1) ZA974033B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2832925B1 (en) * 2001-12-03 2006-07-14 Lipha USE OF 4-OXOBUTANOIC ACID DERIVATIVES IN THE TREATMENT OF INFLAMMATION
JP2012087113A (en) * 2010-09-22 2012-05-10 Daicel Corp Phenylacetic acid compound
WO2015150364A1 (en) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituted benzotriazinone butane acids and use thereof
CN106458938A (en) 2014-04-03 2017-02-22 拜耳制药股份公司 Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
EP3126358A1 (en) * 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015189117A1 (en) * 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE650081A (en) * 1963-07-03
FR2378741A1 (en) * 1977-02-01 1978-08-25 Fabre Sa Pierre GARYL GOXO ISOVALERIC ACIDS WITH ANTIPHLOGISTIC AND ANTALGIC PROPERTIES

Also Published As

Publication number Publication date
CN1225620A (en) 1999-08-11
AR007101A1 (en) 1999-10-13
MY116903A (en) 2004-04-30
DE69706874T2 (en) 2002-03-28
ID17326A (en) 1997-12-18
WO1997043237A1 (en) 1997-11-20
YU18897A (en) 1999-11-22
AU2938997A (en) 1997-12-05
EP0923529A1 (en) 1999-06-23
HRP970247A2 (en) 1998-04-30
JP3354941B2 (en) 2002-12-09
HRP970247B1 (en) 2002-02-28
EP0923529B1 (en) 2001-09-19
ES2160955T3 (en) 2001-11-16
ATE205822T1 (en) 2001-10-15
JPH11510518A (en) 1999-09-14
CO5011113A1 (en) 2001-02-28
ZA974033B (en) 1998-02-19
PA8429501A1 (en) 2000-05-24
BR9709075A (en) 1999-08-03
DE69706874D1 (en) 2001-10-25
CA2253795C (en) 2002-10-15
SV1997000033A (en) 1999-01-14
AU727468B2 (en) 2000-12-14
TW442468B (en) 2001-06-23
CA2253795A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
KR970706260A (en) Imidazole derivatives (IMIDAZOLE DERIVATIVE)
MA30360B1 (en) PYRIMIDINE DERIVATIVES AS INHIBITORS OF PI3K
MA27389A1 (en) NEW BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS.
MA26727A1 (en) NOVEL PYRIMIDINE DERIVATIVES OF SORBITOL DEHYDROGENASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TNSN01008A1 (en) CORTICOTROPHIN RELEASE FACTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MA26718A1 (en) NEW HETEROARYL SUBSTITUTE QUINOLEIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TNSN99236A1 (en) NOVEL SUBSTITUTED BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE69021472T2 (en) Pyrazole derivatives, processes for their preparation and pharmaceutical compositions containing them.
MA28747B1 (en) Pyridine Derivatives
TNSN96172A1 (en) HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
TNSN00104A1 (en) NOVEL ISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX9800577A (en) 4,5-diaryl oxazole derivatives.
KR970701722A (en) PHOSPHONIC DIESTER DERIVATIVE
HUP0402150A2 (en) 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity, process for the preparation, pharmaceutical compositions containing them and their use for production of pharmaceutical compositions
JP2972377B2 (en) Catechol derivatives, pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions containing them
TNSN97086A1 (en) THE SUBSTITUTION OF 4-ALBUTYRIC DERIVATIVE ACIDS AS INHIBITORS OF THE METALLOPROTEASE MATRIX.
TNSN00235A1 (en) NEW HETEROCYCLO-ALKYLSULFONYLPYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
RU2000123169A (en) BENZOTHIADIAZOLES AND THEIR DERIVATIVES
ES2149777T3 (en) DERIVATIVES OF TRIAZOLE THAT HAVE ANTIFUNGAL ACTIVITY.
TNSN98151A1 (en) DERIVATIVES OF 2 - (4 - ARYL - OR HETEROARYL - PIPERAZINE - 1 - YLMETHYL) -1 H - INDOLE.
MA28286A1 (en) Derivatives of 1-N-phenylamino-1H-imidazole and pharmaceutical compositions containing them
KR970707108A (en) (DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
TNSN00250A1 (en) NEW PCP INHIBITOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
DK0780125T3 (en) Use of hydantoin derivatives for the manufacture of a medicament for the treatment of diseases associated with the presence of active oxygen and free radicals
FI104071B (en) Analogous Process for the Preparation of Therapeutically Useful 2,5-Dihydro-2,5-Dioxo-1H-Benzene-β-Azepine Derivatives